A detailed history of Bank Of America Corp transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 428,778 shares of ATHA stock, worth $278,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares
428,778
Previous 228,655 87.52%
Holding current value
$278,705
Previous $605,000 68.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.42 - $3.43 $84,051 - $686,421
200,123 Added 87.52%
428,778 $192,000
Q2 2024

Aug 14, 2024

BUY
$1.92 - $2.71 $485 - $685
253 Added 0.11%
228,655 $605,000
Q1 2024

May 15, 2024

BUY
$2.24 - $4.15 $402,541 - $745,779
179,706 Added 369.04%
228,402 $625,000
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.46 $585,210 - $1.04 Million
-421,015 Reduced 89.63%
48,696 $118,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $9,270 - $14,101
-3,928 Reduced 0.83%
469,711 $1.39 Million
Q1 2023

May 12, 2023

BUY
$2.26 - $4.22 $10,111 - $18,880
4,474 Added 0.95%
473,639 $1.18 Million
Q4 2022

Feb 10, 2023

SELL
$2.76 - $3.71 $55,445 - $74,530
-20,089 Reduced 4.11%
469,165 $1.49 Million
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $178,038 - $240,625
60,764 Added 14.18%
489,254 $1.45 Million
Q2 2022

Aug 12, 2022

BUY
$2.74 - $13.43 $191,109 - $936,715
69,748 Added 19.44%
428,490 $1.31 Million
Q1 2022

May 16, 2022

BUY
$8.96 - $13.51 $1.08 Million - $1.63 Million
120,876 Added 50.82%
358,742 $4.84 Million
Q4 2021

Feb 08, 2022

BUY
$9.17 - $16.39 $225,902 - $403,767
24,635 Added 11.55%
237,866 $3.1 Million
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $1.8 Million - $2.18 Million
196,482 Added 1173.1%
213,231 $2 Million
Q2 2021

Sep 13, 2021

BUY
$10.24 - $20.87 $171,509 - $349,551
16,749 New
16,749 $172,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.6M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.